Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Junfeng Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8630-3090; OpenAlex author ID A5100427793. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
60
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 5 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing… Co-author DOI 10.1158/1078-0432.ccr-25-3359↗
  2. Effect of Radiotherapy in Neoadjuvant Treatment of Borderline Resectable and Locally Advanced Pancreatic Cancer: A Systematic Review and Meta-analysis. First author DOI 10.1097/mpa.0000000000002400↗
  3. The role of histone H1.2 in pancreatic cancer metastasis and chemoresistance. First author DOI 10.1016/j.drup.2023.101027↗
  4. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Last author DOI 10.1007/s10495-023-01843-3↗
  5. The genomic, transcriptomic, and immunological profiles of perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11427-022-2146-5↗
  6. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  7. ERO1L Promotes Hepatic Metastasis through Activating Epithelial-Mesenchymal Transition (EMT) in Pancreatic Cancer. Co-author DOI 10.1155/2021/5553425↗
  8. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  9. Integration of transcriptome and cistrome analysis identifies RUNX1-target genes involved in pancreatic cancer proliferation. Co-author DOI 10.1016/j.ygeno.2020.11.010↗
  10. Establishing and validating a pathway prognostic signature in pancreatic cancer based on miRNA and mRNA sets using GSVA. Co-author DOI 10.18632/aging.103965↗
  11. Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/aging.104091↗
  12. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11866↗
  13. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer. Co-author DOI 10.7150/thno.45124↗
  14. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/8656282↗
  15. Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients. Co-author DOI 10.3892/ol.2018.8452↗
  16. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Last author DOI 10.1080/15384101.2017.1356510↗
  17. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. Co-author DOI 10.7150/jca.20086↗
  18. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review. Co-author DOI 10.1097/md.0000000000003009↗
  19. Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma. Co-author PMID 27648368↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jian‐Yu Yang · 13 shared papers, 2016–2026 · strength 1.42
  2. Yan‐Miao Huo · 13 shared papers, 2016–2026 · strength 1.42
  3. Yongwei Sun · 12 shared papers, 2016–2026 · strength 1.28
  4. Minwei Yang · 11 shared papers, 2016–2026 · strength 1.21
  5. Rong Hua · 11 shared papers, 2016–2023 · strength 1.11
  6. Xueliang Fu · 10 shared papers, 2016–2023 · strength 0.89
  7. Dejun Liu · 8 shared papers, 2016–2023 · strength 0.77
  8. Wei Chiang Liu · 6 shared papers, 2016–2022 · strength 0.54
  9. Huaizhi Wang · 4 shared papers, 2020–2024 · strength 0.49
  10. Jianyou Gu · 3 shared papers, 2020–2024 · strength 0.39
  11. Shixiang Guo · 3 shared papers, 2020–2024 · strength 0.39
  12. Hong Li · 2 shared papers, 2021–2026 · strength 0.37
  13. Zhigang Zhang · 3 shared papers, 2019–2023 · strength 0.35
  14. Huaizhi Wang · 1 shared paper, 2025 · strength 0.33
  15. Peng Tang · 1 shared paper, 2025 · strength 0.33
  16. Yingfang Fan · 2 shared papers, 2020–2024 · strength 0.29
  17. Fuming Xie · 2 shared papers, 2020–2024 · strength 0.29
  18. Jia-Hao Zheng · 2 shared papers, 2022–2023 · strength 0.28
  19. Hong‐Fei Yao · 2 shared papers, 2022–2023 · strength 0.28
  20. Shu‐Heng Jiang · 2 shared papers, 2020–2023 · strength 0.27
  21. Yingbin Liu · 1 shared paper, 2026 · strength 0.26
  22. Zong‐Hao Duan · 1 shared paper, 2026 · strength 0.26
  23. Ruizhe He · 2 shared papers, 2019–2023 · strength 0.23
  24. Bing Ni · 2 shared papers, 2020 · strength 0.20
  25. Xianxing Wang · 2 shared papers, 2020 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.